Dexrazoxane

CHEMBL1738 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
268.3 g/mol
LogP
-1.4
Phase
4

A cardioprotective agent and bisdioxopiperazine prodrug that is hydrolyzed to an EDTA-like compound that chelates intracellular iron, reducing anthracycline-induced cardiac toxicity in cancer patients receiving high cumulative doxorubicin doses. It is also used to treat extravasation injury from anthracycline chemotherapy.

分子量

268.2700 g/mol

LogP

-1.40

TPSA

98.80 Ų

リピンスキーの五則

適合

治療領域

作用機序

Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1

InChI

InChI=1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)/t7-/m0/s1

Molecular Formula

C11H16N4O4

HBD / HBA

2 / 6

回転可能結合数

3

重原子数

19

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

A cardioprotective agent and bisdioxopiperazine prodrug that is hydrolyzed to an EDTA-like compound that chelates intracellular iron, reducing anthracycline-induced cardiac toxicity in cancer patients receiving high cumulative doxorubicin doses. It is also used to treat extravasation injury from anthracycline chemotherapy.

Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.

Yes, Dexrazoxane is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1738. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 71384. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.